Crinetics Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
January 02, 2018 09:00 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Jan. 02, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc., a rare disease therapeutics company focused on endocrine disorders and endocrine-related cancers, today announced that...
Crinetics Pharmaceuticals Initiates Phase 1 Study of Lead Candidate CRN00808 for Acromegaly
October 26, 2017 10:30 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Oct. 26, 2017 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc., a rare disease therapeutics company focused on endocrine disorders and endocrine-related cancers, today announced the...
Crinetics Pharmaceuticals Awarded Two SBIR Grants to Develop New Therapeutics for Congenital Hyperinsulinism and Cushing’s Disease
September 06, 2017 09:00 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Sept. 06, 2017 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc., a rare disease therapeutics company focused on endocrine disorders and endocrine-related cancers, announced today that...
Crinetics Pharmaceuticals Awarded $2.8 Million SBIR Grant to Support Development of Acromegaly Drug Candidate CRN00808
July 13, 2017 13:00 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, July 13, 2017 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc., a rare disease therapeutics company focused on endocrine disorders and endocrine-related cancers, announced today that...